Caldesmon (CALD1) Rabbit Polyclonal Antibody

CAT#: TA332644

Rabbit anti-CALD1 Polyclonal Antibody

Size: 20 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1999.00

CNY 2700.00


货期*
2周

规格
    • 100 ul

Product images

推荐一起购买 (3)
Transient overexpression lysate of caldesmon 1 (CALD1), transcript variant 4
    • 100 ug

CNY 4840.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1430.00


Recombinant protein of human caldesmon 1 (CALD1), transcript variant 3, 20 µg
    • 20 ug

CNY 2900.00
CNY 6650.00

Specifications

Product Data
Applications ELISA, WB
Recommend Dilution WB,1:500 - 1:2000
ELISA,Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Reactivity Human
Host Rabbit
Clonality Polyclonal
Isotype IgG
Formulation Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3.
Concentration lot specific
Purification Affinity purification
Conjugation Unconjugated
Storage Condition Store at -20℃. Avoid freeze / thaw cycles.
Predicted Protein Size 93kDa
Gene Name caldesmon 1
Background This gene encodes a calmodulin- and actin-binding protein that plays an essential role in the regulation of smooth muscle and nonmuscle contraction. The conserved domain of this protein possesses the binding activities to Ca(2+)-calmodulin, actin, tropomyosin, myosin, and phospholipids. This protein is a potent inhibitor of the actin-tropomyosin activated myosin MgATPase, and serves as a mediating factor for Ca(2+)-dependent inhibition of smooth muscle contraction. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms.
Synonyms CDM; H-CAD; HCAD; L-CAD; LCAD; NAG22
Reference Data
Protein Pathways Vascular smooth muscle contraction
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...